115 related articles for article (PubMed ID: 7024139)
21. Prostacyclin in lieu of anticoagulation with heparin for extracorporeal circulation.
Addonizio VP; Fisher CA; Bowen JC; Palatianos GC; Colman RW; Edmunds LH
Trans Am Soc Artif Intern Organs; 1981; 27():304-7. PubMed ID: 7036500
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of platelet factor 3 availability by prostacyclin.
Hársfalvi J; Muszbek L; Stadler I; Fésüs L
Prostaglandins; 1980 Nov; 20(5):935-45. PubMed ID: 7008092
[TBL] [Abstract][Full Text] [Related]
23. Prostacyclin (epoprostenol) as the sole antithrombotic agent in postdilutional hemofiltration.
Canaud B; Mion C; Arujo A; N'Guyen QV; Paleyrac G; Hemmendinger S; Cazenave JP
Nephron; 1988; 48(3):206-12. PubMed ID: 2965311
[TBL] [Abstract][Full Text] [Related]
24. Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration.
Kozek-Langenecker SA; Spiss CK; Michalek-Sauberer A; Felfernig M; Zimpfer M
Crit Care Med; 2003 Mar; 31(3):864-8. PubMed ID: 12626998
[TBL] [Abstract][Full Text] [Related]
25. Prostaglandin releasing polymers - stability and efficacy.
McRea JC; Ebert CD; Kim SW
Trans Am Soc Artif Intern Organs; 1981; 27():511-6. PubMed ID: 7036503
[TBL] [Abstract][Full Text] [Related]
26. Effects of prostacyclin infusion in uremic patients: hematologic and hemodynamic responses.
Zusman RM; Crow JW; Cato AE; Tolkoff-Rubin N
Clin Pharmacol Ther; 1981 Aug; 30(2):251-7. PubMed ID: 7018791
[TBL] [Abstract][Full Text] [Related]
27. [Experimental study upon platelet preservation by prostaglandin I2 during extracorporeal circulation].
Osada H; Kawada T; Hoson M; Funaki S; Arase K; Masaki H; Taira Y; Kuwahara M; Noguchi T
Nihon Kyobu Geka Gakkai Zasshi; 1984 Oct; 32(10):1795-803. PubMed ID: 6394659
[No Abstract] [Full Text] [Related]
28. Effects of PGD2, PGE1, and PGI2-analogues on PGDF-release and aggregation of human gelfiltered platelets.
Stürzebecher S; Nieuweboer B; Matthes S; Schillinger E
Prog Clin Biol Res; 1989; 301():365-9. PubMed ID: 2477855
[No Abstract] [Full Text] [Related]
29. Platelet involvement in the activated coagulation time of heparinized blood.
Moorehead MT; Westengard JC; Bull BS
Anesth Analg; 1984 Apr; 63(4):394-8. PubMed ID: 6367544
[TBL] [Abstract][Full Text] [Related]
30. Heparin counteracts the antiaggregating effect of prostacyclin by potentiating platelet aggregation.
Bertelé V; Roncaglioni MC; Donati MB; de Gaetano G
Thromb Haemost; 1983 Apr; 49(2):81-3. PubMed ID: 6346573
[TBL] [Abstract][Full Text] [Related]
31. Effects of PGI2 and di-butyryl cyclic-AMP on platelets exposed to shear stress.
Hardwick RA; Hellums JD; Peterson DM; Moake J; Olson J
Trans Am Soc Artif Intern Organs; 1981; 27():192-6. PubMed ID: 6277071
[No Abstract] [Full Text] [Related]
32. The effects of prostacyclin (PGI2) on endotoxin shock and endotoxin-induced platelet aggregation in dogs.
Fletcher JR; Ramwell PW
Circ Shock; 1980; 7(3):299-308. PubMed ID: 7004660
[TBL] [Abstract][Full Text] [Related]
33. Effect of prostacyclin (PGI2) on platelets and fibrinolytic activity in patients with arteriosclerosis obliterans.
Dembińska-Kieć A; Kostka-Trabka E; Zumda A; Byrska-Danek A; Bierón K; Grodzińska L; Kedzior A; Zelazny T
Pharmacol Res Commun; 1982 Jun; 14(6):485-98. PubMed ID: 6750655
[No Abstract] [Full Text] [Related]
34. Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men.
Szczeklik A; Gryglewski RJ; Nizankowski R; Musiał J; Pietoń R; Mruk J
Pharmacol Res Commun; 1978 Jun; 10(6):545-56. PubMed ID: 358212
[No Abstract] [Full Text] [Related]
35. [Experimental studies on platelet preservation with prostaglandin I2 and its derivative (OP-41483) during cardiopulmonary bypass].
Takeda H
Hokkaido Igaku Zasshi; 1989 Jul; 64(4):500-11. PubMed ID: 2511131
[TBL] [Abstract][Full Text] [Related]
36. Effects of prostacyclin on platelet aggregation as studied with "filter-loop" technique in the flowing blood of the dog.
Imai S; Matsubara I
Artery; 1980; 8(1):63-72. PubMed ID: 7000043
[TBL] [Abstract][Full Text] [Related]
37. Changes in coagulation and platelet function during prolonged extracorporeal circulation (ECC) in sheep and man.
Fong SW; Burns NE; Williams G; Woldanski C; Gazzaniga AB; Bartlett RH
Trans Am Soc Artif Intern Organs; 1974; 20A():239-47. PubMed ID: 4450343
[No Abstract] [Full Text] [Related]
38. Manipulation of thrombus formation in the hamster cheek pouch with drugs that interact with PGI2 in vitro.
Shishido M; Hirose R; Tanaka K; Katori M
Prostaglandins; 1982 Jun; 23(6):907-17. PubMed ID: 6750694
[TBL] [Abstract][Full Text] [Related]
39. The inhibitory effect of PGI2 (prostacyclin) on white platelet arterial thrombus formation.
Bourgain RH
Haemostasis; 1979; 8(2):117-9. PubMed ID: 387547
[TBL] [Abstract][Full Text] [Related]
40. The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36 374)--equipotent to PGI2 in vitro.
Schrör K; Darius H; Matzky R; Ohlendorf R
Naunyn Schmiedebergs Arch Pharmacol; 1981 Jun; 316(3):252-5. PubMed ID: 6166877
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
